NCT07450664
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
Enrolling by Invitation
Not specifiedAges 4+ObservationalSoleno Therapeutics, Inc.
~200 participants
Updated 2026-05-19 on ClinicalTrials.gov
What's tested:VYKAT XR
At a glance
Recruiting sites
0 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assess safety profile of patients with PWS treated with VYKAT XR.
Measured over Adverse events for each patient will be collected from the time of first dose on VYKAT XR until the last contact with the patient.
Conditions
Where it's being run
15 sites across 14 statesMichigan2
California1
Georgia1
Illinois1
Indiana1
Minnesota1
Missouri1
New Jersey1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients currently receiving or initiating treatment with VYKAT XR, including patients who previously received DCCR or are transitioning from DCCR to VYKAT XR in the context of a prior DCCR clinical trial.
Patients and/or caregivers must provide written informed consent.
What this trial measures
- Assess safety profile of patients with PWS treated with VYKAT XR.Adverse events for each patient will be collected from the time of first dose on VYKAT XR until the last contact with the patient.
The safety profile will be based on adverse events, including nonserious adverse events, serious adverse events, and adverse events leading to discontinuation of VYKAT XR.